Essential Thrombocythemia (ET) — Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Citation(s)
An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)